The UK and US have secured a key commercial pact that will keep zero tariffs on UK pharmaceutical products being sold in the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on drugs through the public health system. This pledge guarantees that import taxes on these vital goods will stay at nothing for a timeframe of three years.
This agreement follows previous statements to dramatically increase duties on patented drug imports, with potential rates discussed as high as 100%.
"This arrangement between the Britain reinforces the global environment for new treatments and introduces long-overdue equity to transatlantic medicine commerce," a release said.
Economic Significance
Pharmaceuticals represent one of the the United Kingdom's biggest exports to the US, which is clearly the primary market for large companies like GSK and AstraZeneca.
Export figures show that in the year to the end of September, the UK sold drugs totaling billions to the US. This value made up 17.4% of all goods exports in that span.
"This agreement secures employment, increases capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The pact entails several notable commitments from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be limited at 15%. In the past, rebates topped 20%.
Recent Tensions
The deal comes amid a protracted tension between the drug companies and the ministers over spending levels and approval rates.
These tensions were intensified by arguments that US patients were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while major investments have been directed toward US facilities.
The Science Minister stated that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its resources over the previous ten-year period.
